The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative
Luis Molinuevo J, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Elsevier Masson
Book Volume: 10
Pages Range: 808-17
Journal Issue: 6
DOI: 10.1016/j.jalz.2014.03.003
Abstract
Cerebrospinal fluid (CSF) biomarkers ?-amyloid 1-42 (A?1-42), also expressed as A?1-42:A?1-40 ratio, T-tau, and P-tau181P, have proven diagnostic accuracy for mild cognitive impairment and Alzheimer's disease (AD). How to use, interpret, and disclose biomarker results drives the need for standardization.Previous Alzheimer's Biomarkers Standardization Initiative meetings discussed preanalytical issues affecting A?1-42 and tau in CSF. This second round of consensus meetings focused on issues related to clinical use of AD CSF biomarkers.Consensus was reached that lumbar puncture for AD CSF biomarker analysis be considered as a routine clinical test in patients with early-onset dementia, at the prodromal stage or with atypical AD. Moreover, consensus was reached on which biomarkers to use, how results should be interpreted, and potential confounding factors.Changes in A?1-42, T-tau, and P-tau181P allow diagnosis of AD in its prodromal stage. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow-up.
Authors with CRIS profile
Involved external institutions
University of Gothenburg / Göteborgs universitet
Sweden (SE)
University of Paris 6 - Pierre et Marie Curie / Université Paris VI Pierre et Marie Curie (UPMC)
France (FR)
Hospital Network Antwerp / Ziekenhuis Netwerk Antwerpen (ZNA)
Belgium (BE)
Université Claude Bernard Lyon 1 (UCB)
France (FR)
Vrije Universiteit Amsterdam (VU) / University Amsterdam
Netherlands (NL)
Università degli Studi di Perugia
Italy (IT)
Sweden (SE)
University of Paris 6 - Pierre et Marie Curie / Université Paris VI Pierre et Marie Curie (UPMC)
France (FR)
Hospital Network Antwerp / Ziekenhuis Netwerk Antwerpen (ZNA)
Belgium (BE)
Université Claude Bernard Lyon 1 (UCB)
France (FR)
Vrije Universiteit Amsterdam (VU) / University Amsterdam
Netherlands (NL)
Università degli Studi di Perugia
Italy (IT)
How to cite
APA:
Luis Molinuevo, J., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret-Liaudet, A.,... Parnetti, L. (2014). The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers & Dementia, 10(6), 808-17. https://doi.org/10.1016/j.jalz.2014.03.003
MLA:
Luis Molinuevo, Jose, et al. "The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative." Alzheimers & Dementia 10.6 (2014): 808-17.
BibTeX: Download